Organisation
Laboratory for Translational Breast Cancer Research
Division
Part of the Department of Oncology that fosters synergy in innovative oncological research. By creating a close link between bed and bench and by capitalizing on advanced technologies, our researchers aim to unravel key molecular mechanisms underlying the development and progression of cancer and to maximize opportunities to translate these findings into better clinical biomarkers, adaptive strategies and innovative treatments.
Current researchers
1 - 10 of 13 results
- Christine Desmedt (Responsible)
- Kristien Borremans (Member)
- Maxim De Schepper (Member)
- Christine Desmedt (Member)
- Tatjana Geukens (Member)
- Edoardo Isnaldi (Member)
- Sophia Leduc (Member)
- Ha Linh Nguyen (Member)
- Anirudh Pabba (Member)
- François Richard (Member)
Projects
1 - 10 of 23
- Atlas of therapeutic targets in metastatic breast cancer.From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- MetLob: A post-mortem tissue donation study dedicated to Metastatic Lobular breast cancerFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Impact of adiposity and lifestyle on breast cancer biology and treatment response.From7 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Histopathological heterogeneity of metastatic breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical and molecular heterogeneity of triple-negative breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of the tumor microenvironment of breast cancer metastasesFrom11 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- LIQUIDEVO: Unravelling breast cancer heterogeneity, progression and treatment resistance in the context of a rapid post-mortem institutional tissue donation program using phylogenetic reconstruction algorithms and an Open Science approach.From1 Oct 2021 → TodayFunding: FWO senior postdoctoral fellowship
- Facing Adiposity in personalizing Treatment of Breast Cancer PatientsFrom1 Mar 2021 → TodayFunding: H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
- Clinical, experimental and molecular characterization of liver metastases from breast cancer patients.From1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 141
- Prognostic Value of the Pace of Tumor Progression as Assessed by Serial F-18-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial(2020)
Authors: Silvia Camera, Tugba Akin Telli, Erwin Woff, Caroline Vandeputte, Pashalina Kehagias, Thomas Guiot, Gabriela Critchi, Yacine Wissam, Giacomo Bregni, Elena Trevisi, et al.
- Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer (vol 20, pg 262, 2020)(2023)
Authors: François Richard
Pages: E281 - E284 - PD-1 protein and gene expression as prognostic factors in early breast cancer(2020)
Authors: François Richard
- Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma(2020)
Authors: Lorenzo Ferrando, Gabriella Cirmena, Anna Garuti, Stefano Scabini, Federica Grillo, Luca Mastracci, Edoardo Isnaldi, Ciro Marrone, Roberta Gonella, Roberto Murialdo, et al.
- Learning lessons from the COVID-19 pandemic for real-world evidence research in oncologydshared perspectives from international consortia(2023)
Authors: Tatjana Geukens
- ESR1 mutations in metastatic lobular breast cancer patients(2019)
Authors: Christine Desmedt, François Richard
- Comprehensive evaluation of methodology to assess abundance of immune infiltrates in breast cancer(2019)
Authors: I Nederlof, D de Bortoli, Y Bareche, GKJ Hooijer, C Sotiriou, MJ van de Vijver, HM Horlings, R Salgado, E Biganzoli, Christine Desmedt
Pages: 2 - 2 - Challenging the current 1-10% cut-off for defining Estrogen Receptor Low Positive grade 2-3 Estrogen Receptor positive, Human Epidermal growth factor Receptor 2 negative early breast cancer(2023)
Authors: Beppe Floris, Christine Desmedt, Ines Nevelsteen, Hans Wildiers, Patrick Neven
- Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases.(2023)
Authors: Yentl Lambrechts, Beppe Floris, Patrick Neven, Ines Nevelsteen, François Richard, Christine Desmedt, Hans Wildiers, Sigrid Hatse
- Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial(2021)
Authors: Christine Desmedt
Pages: 181 - +